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Abstract Benzene-1,2-, 1,3-, and 1,4-di-N-substituted
carbamates (1–15) are synthesized as the constrained ana-
logs of gauche, eclipsed, and anti conformations,
respectively, for the glycerol backbones of triacylglycerol.
Carbamates 1–15 are characterized as the pseudo substrate
inhibitors of cholesterol esterase. Long chain carbamates
are more potent inhibitors than short chain ones. Com-
parison of different geometries for benzene-di-substituted
carbamates, such as benzene-1,2-di-N-octylcarbamate (3)
(ortho-3), benzene-1,3-di-N-octylcarbamate (8) (meta-8),
and benzene-1,4-di-N-octylcarbamates (13) (para-13),
indicates that inhibitory potencies are as followed: meta-
8 [ para-13 [ ortho-3. Therefore, we suggest that the
preferable conformation for the C(sn-1)–O/C(sn-2)–O
glycerol backbone in the enzyme–triacylgycerol complex
is the eclipsed conformation. Meanwhile, kinetic data
indicate that among ortho, meta, and para carbamates,
meta carbamates most resemble the substrate cholesterol
ester.
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Abbreviations
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CEase Cholesterol esterase
LDL Low-density lipoprotein
PNPB p-nitrophenyl butyrate
TX Triton-X 100
1 Introduction
Cholesterol esterase (CEase, EC 3.1.1.13) also known as
bile salt-activated lipase, carboxyl ester lipase, lysophos-
pholipase, and non-specific lipase, is responsible for the
hydrolysis of dietary cholesterol esters, fat soluble vitamin
esters, phospholipids and triacylglycerols. Like the serine
proteases, CEase possesses a catalytic triad, Ser194–
His435–Asp320, that serves as a nucleophilic and general
acid–base catalytic entity [1–3]. Two X-ray structures of
CEase have been reported [4, 5]. Although different bile
salt-activation mechanisms are proposed, the active site of
CEase from two different X-ray crystal structures is similar
to that of lipases.
CEase has also been demonstrated that it is involved
directly in lipoprotein metabolism, in that the enzyme cata-
lyzes the conversion of large low-density lipoprotein (LDL)
to smaller, denser, more cholesterol ester-rich lipoproteins,
and that the enzyme may regulate serum cholesterol levels
[6]. Therefore, the ability of CEase to convert large LDL to
smaller LDL subspecies, and the relationship between
plasma CEase and LDL levels, suggest that high plasma
CEase levels may constitute a potential risk factor for ath-
erosclerosis. Thus, CEase inhibitors may be suitable for the
treatment of combined lipoprotein disorders characterized
by elevation of cholesterol [7–10].
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Aryl carbamates have been characterized as the pseudo
substrate inhibitors of CEase [11–14]. We have reported
that benzene-1,2-di-N-substituted carbamates (1–5) (ortho
carbamates), benzene-1,3-di-N-substituted carbamates (6–
10) (meta carbamates), and benzene-1,4-di-N-substituted
carbamates (11–15) (para carbamates) are the conforma-
tionally constrained analogs of gauche, eclipsed, and anti
conformations (Fig. 1), respectively, for the glycerol
backbones of glycerol lipid such as phosphatidylcholine
in the phospholipase A2 catalysis [15, 16]. Since CEase
also catalyzes the hydrolysis of triacylglycerol, confor-
mations for the glycerol backbone of substrate may also
play an important role in the CEase catalysis. Therefore,
we report here that benzene-di-N-substituted carbamates
(1–15) (Fig. 1) act as the conformationally constrained
analogs of gauche, eclipsed, and anti conformations,
respectively, for the glycerol backbones of triacylglycerol
(substrate).
2 Materials and Methods
2.1 Materials
Porcine pancreatic CEase, p-nitrophenyl butyrate (PNPB),
and triton-X 100 (TX) were obtained from Sigma. All other
chemicals were of the highest purity available
commercially.
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Fig. 1 Three conformations for
the glycerol backbones of
triacylglycerol and chemical
structures of cholesterol ester
and carbamates 1–15
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2.2 Synthesis of Inhibitors
Benzene-1,2-, 1,3-, and 1,4-di-N-substituted carbamates
(1–15) (Fig. 1) were synthesized from the condensation of
catechol, resorcinol, and hydroquinone, respectively, with
three equivalents of the corresponding isocyanate in tri-
ethylamine at 25 C for 24 h (65–90% yield) [17, 18]. The
products were purified by liquid chromatography (silica
gel, hexane-ethyl acetate) and characterized by 1H and 13C
NMR spectra.
2.2.1 Benzene-1,2-di-N-n-butylcarbamate (1)
1H NMR (CDCl3, 400 MHz) d/ppm 0.93 (t, J = 7 Hz, 6H,
x-CH3), 1.35 (sextet, J = 7 Hz, 4H, c-CH2), 1.52 (quintet,
J = 7 Hz, 4H, b-CH2), 3.24 (q, J = 7 Hz, 4H, a-CH2),
5.09 (s, 2H, NH), and 7.15–7.24 (m, 4H, benzene H’s). 13C
NMR (CDCl3, 100 MHz, assignment from DEPT experi-
ments) d/ppm 13.5 (x-CH3), 19.6 (c-CH2), 31.6 (b-CH2),
40.8 (a-CH2), 123.4 (C-4 and C-5 of the benzene ring),
125.8 (C-3 and C-6 of the benzene ring), 143.0 (C-1 and
C-2 of the benzene ring), and 153.9 (carbamate C=O).
2.2.2 Benzene-1,2-di-N-n-hexylcarbamate (2)
1H NMR (CDCl3, 400 MHz) d/ppm 0.88 (t, J = 7 Hz, 6H,
x-CH3), 1.26–1.35 (m, 12H, c- to x-1-CH2), 1.51–1.55
(m, 4H, b-CH2), 3.23 (q, J = 7 Hz, 4H, a-CH2), 5.08
(s, 2H, NH), and 7.15–7.24 (m, 4H, benzene H’s). 13C
NMR (CDCl3, 100 MHz, assignment from DEPT experi-
ments) d/ppm 13.9 (x-CH3), 22.4, 26.3, 29.6 (c-, d-, and
e-CH2), 31.3 (b-CH2), 41.2 (a-CH2), 123.4 (C-4 and C-5 of
the benzene ring), 125.9 (C-3 and C-6 of the benzene ring),
143.0 (C-1 and C-2 of the benzene ring), and 153.9 (car-
bamate C=O).
2.2.3 Benzene-1,2-di-N-n-octylcarbamate (3)
1H NMR (CDCl3, 400 MHz) d/ppm 0.89 (t, J = 7 Hz, 6H,
x-CH3), 1.26–1.30 (m, 20H, c- to x-1-CH2), 1.51–1.57 (m,
4H, b-CH2), 3.23 (q, J = 7 Hz, 4H, a-CH2), 5.06 (s, 2H,
NH), and 7.15–7.24 (m, 4H, benzene H’s). 13C NMR
(CDCl3, 100 MHz, assignment from DEPT experiments)
d/ppm 14.0 (x-CH3), 22.5, 26.2, 26.3, 29.1, 29.7 (c- to
x-1-CH2), 31.7 (b-CH2), 41.2 (a-CH2), 123.4 (C-4 and C-5
of the benzene ring), 126.0 (C-3 and C-6 of the benzene
ring), 143.0 (C-1 and C-2 of the benzene ring), and 153.9
(carbamate C=O).
2.2.4 Benzene-1,2-di-N-t-butylcarbamate (4)
1H NMR (CDCl3, 400 MHz) d/ppm 1.36 (s, 18H, CH3),
5.09 (s, 2H, NH), and 7.15–7.24 (m, 4H, benzene H’s). 13C
NMR (CDCl3, 100 MHz, assignment from DEPT experi-
ments) d/ppm 28.7 (CH3), 50.8 (C(CH3)3), 123.5 (C-4 and
C-5 of the benzene ring), 125.9 (C-3 and C-6 of the the
benzene ring), 142.9 (C-1 and C-2 of the benzene ring), and
151.8 (carbamate C=O).
2.2.5 Benzene-1,2-di-N-benzylcarbamate (5)
1H NMR (CDCl3, 400 MHz) d/ppm 4.33 (d, J = 6 Hz, 4H,
CH2Ph), 5.09 (s, 2H, NH), and 7.15–7.24 (m, 4H, 1,2-
benzene H’s), 7.27–7.30 (m, 10H, phenyl H’s of the benzyl
group). 13C NMR (CDCl3, 100 MHz, assignment from
DEPT experiments) d/ppm 45.3 (benzyl CH2), 123.5,
126.2, 127.4, 127.7, 128.6, 138.1, 142.9 (aromatic C’s),
and 153.9 (carbamate C=O).
2.2.6 Benzene-1,3-di-N-n-butylcarbamate (6)
1H NMR (CDCl3, 400 MHz) d/ppm 0.93 (t, J = 7 Hz, 6H,
x-CH3), 1.37 (sextet, J = 7 Hz, 4H, c-CH2), 1.52 (quintet,
J = 7 Hz, 4H, b-CH2), 3.24 (q, J = 7 Hz, 4H, a-CH2), 4.99
(s, 2H, NH), and 6.90–7.40 (m, 4H, benzene H’s). 13C NMR
(CDCl3, 100 MHz, assignment from DEPT experiments)
d/ppm 13.5 (x-CH3), 19.7 (c-CH2), 31.6 (b-CH2), 40.7
(a-CH2), 115.3 (C-5 of the benzene ring), 118.0 (C-4 and C-6
of benzene ring), 129.0 (C-2 of the benzene ring), 151.4 (C-1
and C-3 of the benzene ring), and 154.2 (carbamate C=O).
2.2.7 Benzene-1,3-di-N-n-hexylcarbamate (7)
1H NMR (CDCl3, 400 MHz) d/ppm 0.88 (t, J = 7 Hz, 6H,
x-CH3), 1.30–1.35 (m, 12H, c- to x-1-CH2), 1.52–1.57
(m, 4H, b-CH2), 3.23 (q, J = 7 Hz, 4 H, a-CH2), 4.98
(s, 2H, NH), and 6.90–7.35 (m, 4H, benzene H’s). 13C
NMR (CDCl3, 100 MHz, assignment from DEPT experi-
ments) d/ppm 13.9 (x-CH3), 22.4, 26.3, 29.6 (c-, d-, and
e-CH2), 31.3 (b-CH2), 41.2 (a-CH2), 115.3 (C-5 of the
benzene ring), 118.1 (C-4 and C-6 of the benzene ring),
129.1 (C-2 of the benzene ring), 151.4 (C-1 and C-3 of the
benzene ring), and 154.2 (carbamate C=O).
2.2.8 Benzene-1,3-di-N-n-octylcarbamate (8)
1H NMR (CDCl3, 400 MHz) d/ppm 0.88 (t, J = 7 Hz, 6H,
x-CH3), 1.26–1.33 (m, 20H, c- to x-1-CH2), 1.52–1.57 (m,
4H, b-CH2), 3.23 (q, J = 7 Hz, 4H, a-CH2), 4.97 (s, 2H,
NH), and 6.90–7.35 (m, 4H, benzene H’s). 13C NMR
(CDCl3, 100 MHz, assignment from DEPT experiments)
d/ppm 14.0 (x-CH3), 22.6, 26.7, 29.1, 29.2, 29.7 (c- to
x-1-CH2), 31.7 (b-CH2), 41.2 (a-CH2), 115.3 (C-5 of the
benzene ring), 118.2 (C-4 and C-6 of the benzene ring),
129.2 (C-2 of the benzene ring), 151.5 (C-1 and C-3 of the
benzene ring), and 154.2 (carbamate C=O).
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2.2.9 Benzene-1,3-di-N-t-butylcarbamate (9)
1H NMR (CDCl3, 400 MHz) d/ppm 1.36 (s, 18 H, CH3),
5.09 (s, 2H, NH), and 6.90–7.35 (m, 4H, benzene H’s). 13C
NMR (CDCl3, 100 MHz, assignment from DEPT experi-
ments) d/ppm 28.7 (CH3), 50.8 (C(CH3)3), 115.3 (C-5 of
the benzene ring), 118.3 (C-4 and C-6 of the benzene ring),
129.2 (C-2 of benzene ring), 151.3 (C-1 and C-3 of the
benzene ring), and 152.3 (carbamate C=O).
2.2.10 Benzene-1,3-di-N-benzylcarbamate (10)
1H NMR (CDCl3, 400 MHz) d/ppm 4.43 (d, J = 2 Hz, 4H,
CH2Ph), 5.09 (s, 2H, NH), 6.90–7.35 (m, 4H, benzene H’s),
and 7.27–7.37 (m, 10H, phenyl H’s of the benzyl group).
13C NMR (CDCl3, 100 MHz, assignment from DEPT
experiments) d/ppm 45.3 (benzyl CH2), 115.3, 118.4,
127.7, 127.8, 128.8, 129.4, 137.9, 151.4 (aromatic C’s),
and 154.2 (carbamate C=O).
2.2.11 Benzene-1,4-di-N-n-butylcarbamate (11)
1H NMR (CDCl3, 400 MHz) d/ppm 0.93 (t, J = 7 Hz, 6H,
x-CH3), 1.37 (sextet, J = 7 Hz, 4H, c-CH2), 1.53 (quintet,
J = 7 Hz, 4H, b-CH2), 3.24 (q, J = 7 Hz, 4H, a-CH2),
4.98 (s, 2H, NH), and 7.07 (s, 4H, benzene H’s). 13C NMR
(CDCl3, 100 MHz, assignment from DEPT experiments)
d/ppm 13.7 (x-CH3), 19.9 (c-CH2), 31.8 (b-CH2), 40.9
(a-CH2), 122.2 (C-2, C-3, C-5 and C-6 of the benzene
ring), 148.0 (C-1 and C-4 of the benzene ring), and 154.5
(carbamate C=O).
2.2.12 Benzene-1,4-di-N-n-hexylcarbamate (12)
1H NMR (CDCl3, 400 MHz) d/ppm 0.88 (t, J = 7 Hz, 6H,
x-CH3), 1.30–1.35 (m, 12H, c- to x-1-CH2), 1.52–1.55
(m, 4H, b-CH2), 3.24 (q, J = 7 Hz, 4H, a-CH2), 4.97
(s, 2H, NH), and 7.07 (s, 4H, benzene H’s). 13C NMR
(CDCl3, 100 MHz, assignment from DEPT experiments)
d/ppm 14.0 (x-CH3), 22.5, 26.4, 29.7 (c-, d-, and e-CH2),
31.4 (b-CH2), 41.3 (a-CH2), 122.2 (C-2, C-3, C-5 and C-6
of the benzene ring), 148.0 (C-1 and C-4 of the benzene
ring), and 154.5 (carbamate C=O).
2.2.13 Benzene-1,4-di-N-n-octylcarbamate (13)
1H NMR (CDCl3, 400 MHz) d/ppm 0.87 (t, J = 7 Hz, 6H,
x-CH3), 1.26–1.30 (m, 20H, c- to x-1-CH2), 1.52–1.55 (m,
4H, b-CH2), 3.24 (q, J = 7 Hz, 4H, a-CH2), 4.97 (s, 2H,
NH), and 7.07 (s, 4H, benzene H’s). 13C NMR (CDCl3,
100 MHz, assignment from DEPT experiments) d/ppm
14.0 (x-CH3), 22.6, 26.7, 29.1, 29.2, 29.8 (c- to x-1-CH2),
31.7 (b-CH2), 41.3 (a-CH2), 122.2 (C-2, C-3, C-5 and C-6
of the benzene ring), 148.0 (C-1 and C-4 of the benzene
ring), and 154.5 (carbamate C=O).
2.2.14 Benzene-1,4-di-N-t-butylcarbamate (14)
1H NMR (CDCl3, 400 MHz) d/ppm 1.36 (s, 18 H, CH3),
5.09 (s, 2 H, NH), and 7.06 (s, 4 H, benzene H’s). 13C
NMR (CDCl3, 100 MHz, assignment from DEPT experi-
ments) d/ppm 29.0 (CH3), 51.1 (C(CH3)3), 122.6 (C-2, C-3,
C-5 and C-6 of the benzene ring), 148.1 (C-1 and C-4 of
the benzene ring), and 152.9 (carbamate C=O).
2.2.15 Benzene-1,4-di-N-benzylcarbamate (15)
1H NMR (CDCl3, 400 MHz) d/ppm 4.34 (d, J = 6 Hz, 4H,
CH2Ph), 5.09 (s, 2H, NH), and 7.09 (s, 4H, 1,2-benzene
H’s), 7.28–7.35 (m, 10H, phenyl H’s of the benzyl group).
13C NMR (CDCl3, 100 MHz, assignment from DEPT
experiments) d/ppm 45.3 (benzyl CH2), 122.1 (C-2, C-3,
C-5 and C-6 of the benzene ring), 127.4, 127.9, 128.7,
140.0 (phenyl C’s of the benzyl group), 149.0 (C-1 and C-4
of the benzene ring), and 154.9 (carbamate C=O).
2.3 Instrumental Methods
All steady state kinetic data were obtained from an UV–
Visible spectrometer (Agilent 8453) with a cell holder
circulated with a water bath. 1H and 13C NMR spectra were
recorded in CDCl3 at 400 and 100 MHz, respectively,
(Varian Gemini-400 spectrometer) with an internal refer-
ence tetramethylsilane at 25 C.
2.4 Data Reduction
Origin (version 6.0) was used for linear and nonlinear least-
squares curve fittings.
2.5 CEase Inhibition
CEase inhibition reactions were determined as described
by Hosie et al [11–14]. CEase-catalyzed hydrolysis of
PNPB in the presence of carbamates 1–15 was followed
continuously at 410 nm on the UV–Visible spectrometer.
The temperature was maintained at 25.0 C by a refriger-
ated circulating water bath. All reactions were preformed
in sodium phosphate buffer (1 mL, 0.1 M, pH 7.0) con-
taining NaCl (0.1 M), CH3CN (2% by volume), detergent
triton-X 100 (TX) (0.5% by weight), substrate PNPB
(0.1 mM), and varying concentration of the inhibitors.
Requisite volumes of stock solution of substrate PNPB and
the inhibitor in acetonitrile were injected into reaction
buffer via a pipet. CEase was dissolved in sodium
Benzene-di-N-Substituted Carbamates 279
123
phosphate buffer (0.1 M, pH 7.0). Carbamates 1–15 were
characterized as the pseudo or alternate substrate inhibitors
of CEase (Scheme 1) [11–14, 19, 20]. The carbamylation
stage was rapid compared to subsequent decarbamylation
(k2  k3), thus the two steps are easily resolved kinetically
[11–13, 21]. The apparent inhibition constant (1 + [S]/Km)
Ki and carbamylation constant (k2) were obtained from the
nonlinear least-squares curve fitting of the kapp vs. [I] plot
against Eq. 1 (Fig. 2). The inhibition constant Ki was then
calculated form the apparent inhibition constant when both
[S] and Km values for the CEase-catalyzed hydrolysis of
PNPB were known (Table 1). The Km value for the CEase
catalyzed hydrolysis of PNPB was 100 ± 20 lM obtained
from Michaelis–Menten equation. The bimolecular rate
constant, ki = k2/Ki, was related to overall inhibitory
potency.
kapp ¼ k2½I= Ki 1 þ ½S=Kmð Þ þ ½Ið Þ ð1Þ
Duplicate sets of data were collected for each inhibitor
concentration.
3 Results and Discussion
3.1 Pseudo Substrate Inhibition of CEase
by Carbamates 1–15
Since the inhibition of CEase by carbamates 1–15 follows
first-order kinetics over the observed time period for the
steady-state kinetics, first-order rate constant, kapp, for
pseudo substrate inhibition is determined from Eq. 1
[11–14, 19]. Therefore, carbamates 1–15 are characterized
E + S
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Scheme 1 Kinetic scheme for pseudo substrate inhibitions of CEase
by carbamates 1–15 in the presence of substrate. E: enzyme, CEase;
E-A: acyl enzyme; EI: enzyme-inhibitor Michaelis complex; E-I0:
carbamyl enzyme; ES: enzyme-substrate Michaelis complex; I:
pseudo substrate inhibitor, 1-15; k2: carbamyl constant; k3: decarb-
amylation constant; kcat: turnover number; kd: deacylation constant;
Ki: inhibition constant; Km: Michaelis-Menten constant; P: product,
2-N-substituted-carbamylphenol; P0: product, p-nitrophenol; P0 0:
product, butyrate; Q: product, acylate; S: substrate, PNPB
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Fig. 2 Nonlinear least-squares curve fittings of kapp vs. inhibitor
concentration ([I]) plot against Eq. 1 for the pseudo-substrate inhibition
[11–14] of CEase by (a) ortho-3, (b) meta-8, and (c) para-13. The
parameters of the fit were (a) k2 = 0.00096 ± 0.00002 s
-1, Ki =
7 ± 2 lM, and R2 = 0.99483; (b) k2 = 0.00064 ± 0.00003 s
-1, Ki =
0.4 ± 0.1 lM, and R2 = 0.99163; and (c) k2 = 0.00050 ± 0.00001
s-1, Ki = 0.7 ± 0.1 lM, and R
2 = 0.99418. CEase-catalyzed hydroly-
sis of PNPB in the presence of carbamate 3, 8 or 13 was followed
continuously at 410 nm on the UV–Visible spectrometer at 25.0 C. All
reactions were preformed in sodium phosphate buffer (1 mL, 0.1 M, pH
7.0) containing NaCl (0.1 M), CH3CN (2% by volume), detergent
triton-X 100 (TX) (0.5% by weight), substrate PNPB (0.1 mM), and
varying concentration of the inhibitors
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as the pseudo substrate inhibitors of CEase (Scheme 1),
and the inhibition data are summarized in Table 1.
Since carbamates 1–15 are characterized as the pseudo
substrate inhibitors of CEase, one carbamate group of
carbamates 1–15 must bind to the acyl group binding site
(ACS) of active site [4, 5], which is located deeply inside
the enzyme. Meanwhile, the first step for this pseudo
substrate inhibition is formation of the enzyme-inhibitor
complex from an attack of the serine residue of the enzyme
to one of the two carbamate carbonyl carbons of the
inhibitor with the inhibition constant, Ki. The second step
(k2) is the carbamylation step and formation of the carba-
myl enzyme. That all k2 values are about the same
(Table 1) indicates that the k2 step is basically independent
upon the shape of the leaving group.
3.2 Comparisons of Inhibitory Potencies of CEase
by Different Substituents on Carbamates 1–15
When n-butyl, n-hexyl, n-octyl, t-butyl, and benzyl carba-
mate substituents are compared in a series of compounds
such as benzene-1,2-di-N-substituted carbamates (1–5)
(Fig. 1) for the CEase inhibition, the long chain substituted
inhibitors are more potent than the short chain ones and
more bulky inhibitors are less potent than less bulky ones
(Table 1, Fig. 3). Since the shape of ACS of CEase looks
like a deep, narrow tunnel [4, 5], CEase binds preferably to
the long chain inhibitors.
3.3 Comparisons of Inhibitory Potencies for CEase
by ortho Carbamates 1–5, meta Carbamates 6–10,
and para Carbamates 11–15
In this paper, ortho, meta, and para benzene-di-substituted
carbamates (1–15) are synthesized as the constrained
analogs of gauche, eclipsed, and anti conformations for
the glycerol backbones of triacylglycerol (substrate),
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Fig. 3 Comparisons of the ki values of the CEase inhibitions by
inhibitors 1–15
Table 1 The k2, Ki and ki values
a of the CEase inhibitions by ben-
zene-di-N-substituted carbamates (1–15)
Inhibitors Ki (lM) k2 (10
-3 s-1) ki (10
3 M-1 s-1)
1 27 ± 4 7.0 ± 0.2 0.27 ± 0.03
2 20 ± 2 12.4 ± 0.2 0.61 ± 0.08
3 7 ± 2 9.6 ± 0.2 1.3 ± 0.5
4 30 ± 6 5.49 ± 0.07 0.20 ± 0.05
5 4 ± 2 6.9 ± 0.3 2 ± 1
6 1.2 ± 0.6 9.5 ± 0.5 7 ± 3
7 1.0 ± 0.2 11.2 ± 0.3 12 ± 2
8 0.4 ± 0.1 6.4 ± 0.3 18 ± 8
9 1.6 ± 0.3 7.80 ± 0.05 5 ± 1
10 1.7 ± 0.5 6.9 ± 0.2 4 ± 1
11 1.8 ± 0.6 6.7 ± 0.3 3 ± 1
12 1.2 ± 0.4 6.7 ± 0.6 5 ± 2
13 0.7 ± 0.1 5.0 ± 0.1 7 ± 1
14 2 ± 1 6.4 ± 0.8 3 ± 2
15 5 ± 1 7.2 ± 0.2 1.5 ± 0.3
a Ki (1 + [S]/Km) values were obtained from the nonlinear least-
squares curve fittings of kapp vs. [I] plot against Eq. 1 (Fig. 2) where
[PNPB] = 100 lM and the Km value for the CEase catalyzed
hydrolysis of PNPB was 100 ± 20 lM which was calculated from
Michaelis–Menten equation in the absence of any pseudo or alternate
substrate inhibitor. ki = k2/Ki
O
O
N
O
N
O
O
N
O
N
O
O
O
N
O
N
O
O
cholesterol ester
meta-6
para-11
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Fig. 4 Superimposition of cholesterol ester (black), ortho-1 (red),
meta-6 (green), and para-11 (blue)
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respectively (Fig. 1). Among ortho, meta, and para ben-
zene-di-substituted carbamates such as compounds ortho-3,
meta-8, and para-13, meta carbamates are always the most
potent inhibitors of CEase (Table 1, Fig. 3). In other
words, the best position for the second carbamate group of
the above three inhibitors is 120 to the first carbamate
group (Fig. 1). Accordingly, the glycerol backbone con-
formation in the enzyme-substrate tetrahedral complex
prefers the eclipsed conformation. Meanwhile, superim-
position of ortho, meta, and para inhibitors and the
substrate cholesterol ester together indicates that meta
inhibitor most resemble cholesterol ester (Fig. 4).
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